BioCentury | Feb 20, 2020
Finance

With $88M series B, Spruce seeks short path to approval in rare endocrine disorder

Spruce Biosciences hopes two rounds of financing will be enough to deliver pivotal data for its lead program, which takes a non-steroidal approach to treating endocrine disorders such as classic congenital adrenal hyperplasia (CAH). Omega...
BC Extra | Jun 22, 2019
Financial News

Mirum, Fulcrum file for IPOs

On Friday, Mirum and Fulcrum each filed to raise up to $86.3 million in NASDAQ IPOs. Mirum Pharmaceuticals Inc. (San Francisco, Calif.) launched in November with a $120 million series A round led by New...
BioCentury | May 20, 2019
Emerging Company Profile

Reneo: Small molecules for rare mitochondrial diseases

With a $50 million series A led by NEA and a management team guided by veterans of Shire takeout Lumena, Reneo believes its small molecule could carve out a niche in the rare genetic mitochondrial...
BC Extra | Mar 25, 2019
Financial News

Arch Oncology raises $50M series B to develop anti-CD47 mAb

Backed by new investor Lightchain, Arch Oncology raised $50 million in a series B round to enable the company to advance its anti-CD47 mAb, AO-176, which is in a Phase I trial to treat solid...
BC Week In Review | Dec 21, 2018
Financial News

RiverVest closes fourth life science venture fund

RiverVest Venture Partners announced the final close of RiverVest Venture Fund IV at $184.4 million. The firm has invested in eight companies from the fund to date, including cancer company OncoResponse Inc. (Houston, Texas) and...
BC Extra | Dec 18, 2018
Financial News

RiverVest closes new fund at $184.4M

RiverVest Venture Partners announced the final close of RiverVest Venture Fund IV at $184.4 million. The firm has invested in eight companies from the fund to date, including cancer company OncoResponse Inc. (Houston, Texas) and...
BC Week In Review | Nov 9, 2018
Company News

Mirum launches with liver disease candidates from Shire

Mirum Pharmaceuticals Inc. (San Francisco, Calif.) launched with a $120 million series A round and a license from Shire plc (LSE:SHP; NASDAQ:SHPG) to a pair of candidates to treat liver diseases. The start-up intends to...
BC Extra | Nov 7, 2018
Financial News

Mirum launches with liver disease candidates from Shire

Mirum Pharmaceuticals Inc. (San Francisco, Calif.) launched with a $120 million series A round and a license from Shire plc (LSE:SHP; NASDAQ:SHPG) to a pair of candidates to treat liver diseases. The start-up intends to...
BC Week In Review | Sep 14, 2018
Financial News

OncoResponse to move into clinic with $40M series B

OncoResponse Inc. (Houston, Texas) raised $40 million in a series B round led by RiverVest Venture Partners. Fellow new investors Qatar Investment Authority and Redmile Group participated, as did existing investors Alexandria Venture Investments, Arch...
BC Extra | Sep 11, 2018
Financial News

OncoResponse to move into clinic with $40M series B

OncoResponse Inc. (Houston, Texas) raised $40 million in a series B round led by RiverVest Venture Partners. Fellow new investors Qatar Investment Authority and Redmile Group participated, as did existing investors Alexandria Venture Investments, Arch...
Items per page:
1 - 10 of 94
BioCentury | Feb 20, 2020
Finance

With $88M series B, Spruce seeks short path to approval in rare endocrine disorder

Spruce Biosciences hopes two rounds of financing will be enough to deliver pivotal data for its lead program, which takes a non-steroidal approach to treating endocrine disorders such as classic congenital adrenal hyperplasia (CAH). Omega...
BC Extra | Jun 22, 2019
Financial News

Mirum, Fulcrum file for IPOs

On Friday, Mirum and Fulcrum each filed to raise up to $86.3 million in NASDAQ IPOs. Mirum Pharmaceuticals Inc. (San Francisco, Calif.) launched in November with a $120 million series A round led by New...
BioCentury | May 20, 2019
Emerging Company Profile

Reneo: Small molecules for rare mitochondrial diseases

With a $50 million series A led by NEA and a management team guided by veterans of Shire takeout Lumena, Reneo believes its small molecule could carve out a niche in the rare genetic mitochondrial...
BC Extra | Mar 25, 2019
Financial News

Arch Oncology raises $50M series B to develop anti-CD47 mAb

Backed by new investor Lightchain, Arch Oncology raised $50 million in a series B round to enable the company to advance its anti-CD47 mAb, AO-176, which is in a Phase I trial to treat solid...
BC Week In Review | Dec 21, 2018
Financial News

RiverVest closes fourth life science venture fund

RiverVest Venture Partners announced the final close of RiverVest Venture Fund IV at $184.4 million. The firm has invested in eight companies from the fund to date, including cancer company OncoResponse Inc. (Houston, Texas) and...
BC Extra | Dec 18, 2018
Financial News

RiverVest closes new fund at $184.4M

RiverVest Venture Partners announced the final close of RiverVest Venture Fund IV at $184.4 million. The firm has invested in eight companies from the fund to date, including cancer company OncoResponse Inc. (Houston, Texas) and...
BC Week In Review | Nov 9, 2018
Company News

Mirum launches with liver disease candidates from Shire

Mirum Pharmaceuticals Inc. (San Francisco, Calif.) launched with a $120 million series A round and a license from Shire plc (LSE:SHP; NASDAQ:SHPG) to a pair of candidates to treat liver diseases. The start-up intends to...
BC Extra | Nov 7, 2018
Financial News

Mirum launches with liver disease candidates from Shire

Mirum Pharmaceuticals Inc. (San Francisco, Calif.) launched with a $120 million series A round and a license from Shire plc (LSE:SHP; NASDAQ:SHPG) to a pair of candidates to treat liver diseases. The start-up intends to...
BC Week In Review | Sep 14, 2018
Financial News

OncoResponse to move into clinic with $40M series B

OncoResponse Inc. (Houston, Texas) raised $40 million in a series B round led by RiverVest Venture Partners. Fellow new investors Qatar Investment Authority and Redmile Group participated, as did existing investors Alexandria Venture Investments, Arch...
BC Extra | Sep 11, 2018
Financial News

OncoResponse to move into clinic with $40M series B

OncoResponse Inc. (Houston, Texas) raised $40 million in a series B round led by RiverVest Venture Partners. Fellow new investors Qatar Investment Authority and Redmile Group participated, as did existing investors Alexandria Venture Investments, Arch...
Items per page:
1 - 10 of 94